Market Checkup: Johnson & Johnson's Second Quarter
In today's edition of Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at Johnson & Johnson, the largest health-care company in the Dow. They discuss the key takeaways from Johnson & Johnson's second-quarter results and look at its main opportunities in the medical device, pharmaceutical, and consumer health-care spaces.
One of the best parts of owning big pharma stocks is their attractive dividends, but smart investors know the importance of diversifying -- seeking high-yielding stocks from multiple industries. The Motley Fool's special free report "Secure Your Future With 9 Rock-Solid Dividend Stocks" outlines the Fool's favorite dependable dividend-paying stocks across all sectors. Grab your free copy by clicking here.
The article Market Checkup: Johnson & Johnson's Second Quarter originally appeared on Fool.com.David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson and Vertex Pharmaceuticals and owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.